Results 231 to 240 of about 838,557 (301)
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra +4 more
wiley +1 more source
Rapid Symptomatic Improvement and Long-Term Minimal Symptom Expression in a Myasthenia Gravis Patient Treated With Zilucoplan Without Maintenance Cholinesterase Inhibitors, Corticosteroids, or Immunosuppressants: A Case Report. [PDF]
Amano R.
europepmc +1 more source
Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis. [PDF]
Nada EA +10 more
europepmc +1 more source
Phenotype and genotype of hypophosphatasia cases in Saudi Arabia: multi-center case cohort. [PDF]
Alsagheir A +12 more
europepmc +1 more source
Rarely listed essential medicines in 158 national lists. [PDF]
Ul Haq MZ +4 more
europepmc +1 more source
The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer. [PDF]
Bracken-Clarke D +16 more
europepmc +1 more source

